Welcome to our dedicated page for DiagnaMed Holdings news (Ticker: DGNMF), a resource for investors and traders seeking the latest updates and insights on DiagnaMed Holdings stock.
DiagnaMed Holdings Corp (DGNMF) delivers innovative healthcare solutions through its BRAIN AGE® AI diagnostics and molecular hydrogen therapy research. This news hub provides investors and medical professionals with essential updates on the company's technological advancements and clinical initiatives.
Access real-time information about regulatory milestones, research partnerships, and product development progress. Our curated news collection covers earnings announcements, clinical trial updates, and strategic collaborations with research institutions across neurology and clean energy sectors.
Discover how DiagnaMed's dual focus on AI-powered brain health assessments and hydrogen-based therapeutics positions it at the forefront of neurotechnology innovation. Stay informed about developments in EEG analysis platforms and pharmaceutical-grade hydrogen applications through verified press releases and objective reporting.
Bookmark this page for streamlined access to DiagnaMed's latest financial disclosures, technology patents, and peer-reviewed study results. Regularly updated content ensures you never miss critical updates about this pioneer in cognitive health solutions.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has successfully closed its private placement offering, raising $397,510 through the issuance of 13,250,333 units at $0.03 per unit. Each unit includes one common share and one purchase warrant, allowing holders to acquire an additional share at $0.05 within 24 months.
The company paid $29,760.80 in finders' fees and issued 992,027 finder warrants. The net proceeds will fund research, development, and commercialization of their hydrogen production and monitor technology and BRAIN AGE® Brain Health AI Platform, along with general corporate purposes.
Chairman and CEO Fabio Chianelli participated in the offering, subscribing for 850,000 units ($25,500). This related party transaction is exempt from formal valuation and minority shareholder approval requirements as it represents less than 25% of the company's market capitalization.
DiagnaMed Holdings (OTCQB: DGNMF) has received FDA Orphan Drug Designation for molecular hydrogen in treating Amyotrophic Lateral Sclerosis (ALS). This designation supports the development of treatments for this rare neuromuscular disease that affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases annually.
Molecular hydrogen, known for its antioxidant and anti-inflammatory properties, has shown promising results in preclinical studies for mitigating oxidative stress and inflammation in ALS progression. The designation provides key benefits including tax credits for clinical trials, FDA fee exemptions, and potential seven-year market exclusivity upon approval.
Additionally, DiagnaMed has entered a non-binding letter of intent with Revive Therapeutics dated February 28, 2025, to acquire full rights to DiagnaMed's intellectual property related to molecular hydrogen for ALS. The acquisition is expected to close by March 31, 2025, subject to due diligence and definitive agreement.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced a private placement offering of units, targeting between $350,000 and $510,000 at $0.03 per unit. Each unit consists of one common share and one purchase warrant, with warrants exercisable at $0.05 for 24 months from closing.
The offering, led by EMD Financial Inc, will support:
- Research, development and commercialization of hydrogen production and monitor technology
- BRAIN AGE® Brain Health AI Platform
- General corporate and working capital purposes
The company may pay finder's fees including up to 8% cash commission and 8% finder warrants. The offering, closing around March 31, 2025, will be available to Canadian residents (except Quebec) under the Listed Issuer Financing Exemption, with no resale restrictions.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced its support for Québec Innovative Materials Corp (QIMC) in establishing hydrogen as a primary energy source in Quebec. This initiative aligns with Quebec's goals to reduce emissions by 38% by 2030 and achieve net-zero by 2050.
The collaboration focuses on QIMC's natural hydrogen production potential in the Lake Timiskaming Graben, specifically in St-Bruno-de-Guigues. DiagnaMed will support QIMC using its proprietary electromagnetic heating technology for hydrogen extraction, developed by Dr. Qingwang Yuan at Texas Tech University's HOPE Group.
According to CEO Fabio Chianelli, QIMC's St. Bruno-de-Guigues property findings could have a potential commercial value in the billions of dollars. The company aims to produce cost-effective, carbon-neutral hydrogen using their direct extraction technology.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) announces progress in commercializing its proprietary electromagnetic heating technology for hydrogen production. The technology, developed by Dr. Qingwang Yuan at Texas Tech University, enables direct hydrogen extraction from petroleum reservoirs and natural hydrogen fields.
The company is integrating this newly licensed technology into existing production systems to improve efficiency and cost-effectiveness. DiagnaMed has strengthened its partnership with Québec Innovative Materials Corp. (QIMC) to expand renewable energy applications.
DiagnaMed aims to repurpose over 25,000 active oil and gas fields and 2-3 million abandoned wells in the United States for hydrogen extraction. The company is currently in discussions with petroleum and natural hydrogen exploration companies for potential partnerships.
DiagnaMed Holdings Corp. (DGNMF) has announced a strategic collaboration with TerraVent Environmental Inc. to advance two hydrogen production technologies. The first technology, developed by Dr. Qingwang Yuan at Texas Tech University, combines hydraulic fracturing with electromagnetic heating to extract hydrogen from oil, gas, and shale reservoirs at costs as low as $0.86 per kilogram.
The second technology, developed by TerraVent, stimulates naturally occurring hydrogen generation using electromagnetic heat, with expected production costs at approximately half of the U.S. Department of Energy's $1/kg goal for 2031. The partnership will leverage existing infrastructure, including over 25,000 active oil and gas fields globally and 2-3 million abandoned wells in the United States.
This collaboration builds on DiagnaMed's recent partnership with Québec Innovative Materials Corp. at their St-Bruno-de-Guigues Hydrogen Project, where test results showed hydrogen concentration measurements reaching 7,119 ppm and maintaining 2,886 ppm, with several other measurements above 550 ppm.
DiagnaMed Holdings (CSE: DMED, OTCQB: DGNMF) has announced two significant corporate updates. First, Elyssia Patterson has resigned from the company's board of directors. Second, the company has issued 1,000,000 stock options to consultants with an exercise price of $0.05 per common share. These options have a five-year expiration term and will vest in four equal installments over a one-year period, with the first quarter vesting at three months and subsequent quarters vesting at six, nine, and twelve months from the grant date.
DiagnaMed Holdings Corp. (CSE: DMED, OTCQB: DGNMF) has announced a strategic partnership with Québec Innovative Materials Corp. (QIMC) to implement DiagnaMed's hydrogen extraction technology at QIMC's Ville Marie Hydrogen Project in Québec.
The collaboration centers on DiagnaMed's patented technology (WO2023044149A1), developed by Dr. Qingwang Yuan at Texas Tech University. This innovative method combines hydraulic fracturing with electromagnetic wave heating to extract hydrogen from various sources, including light oil, gas, shale reservoirs, and ultramafic rock formations.
The technology promises hydrogen production costs as low as $0.86 per kilogram, aligning with the U.S. Department of Energy's goal of achieving $1/kg hydrogen production by 2031. As part of the agreement, QIMC will receive 2,000,000 shares of DMED.
DiagnaMed Holdings (CSE: DMED, OTCQB: DGNMF), a frontrunner in hydrogen-producing technologies and AI medical applications, has announced a strategic partnership with Texas Tech University. This collaboration aims to commercialize a revolutionary technology (WO2023044149A1) for producing hydrogen directly from petroleum reservoirs and natural hydrogen fields.
Developed by Dr. Qingwang Yuan of the HOPE Group at Texas Tech, the technology combines hydraulic fracturing with electromagnetic wave heating to generate hydrogen from light oil, gas, and shale reservoirs, as well as ultramafic rock formations. With production costs potentially as low as $0.86 per kilogram, it aligns with the U.S. Department of Energy's goal of achieving $1/kg hydrogen by 2031.
Fabio Chianelli, Chairman and CEO of DiagnaMed, highlighted the technology's potential to transform over 25,000 active oil and gas fields globally and repurpose 2-3 million abandoned wells in the U.S. This innovation not only addresses global clean energy demands but also aims to reduce greenhouse gas emissions and deliver cost-effective, carbon-zero hydrogen.
Supported by a Techno-Economic Analysis from Argonne National Laboratory, this first-of-its-kind technology enhances energy efficiency and reduces costs and carbon footprints. As global hydrogen demand is expected to grow significantly, DiagnaMed’s partnership with Texas Tech positions it as a leader in the clean energy sector.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) has partnered with EIREX to develop and commercialize a novel hydrogen extraction technology from water. The EIREX technology aims to produce hydrogen at $0.25 per kilogram for pilot prototypes and $0.10 per kilogram for commercial units, significantly lower than the industry's 2030 target of $2 per kilogram. The global hydrogen market, valued at $170.14 billion in 2023, is expected to grow at a 9.3% CAGR through 2030. The collaboration focuses on developing commercial pilot prototypes and establishing partnerships with healthcare facilities for operational and medical treatment purposes.
